Browsing Tag
Leniolisib
3 posts
Pharming Group tightens 2026 revenue guidance to $380m–$390m after strong third-quarter sales
Pharming Group Q3 revenue rises 21% to $117.6 million as Joenja sales jump 58%. Explore revised guidance, expenses and investor outlook.
Pharming expands Joenja into children as rare-disease growth offsets RUCONEST pressure
Pharming has secured FDA approval for Joenja in children aged four to 11 weighing at least 27 kg, widening a rare-disease franchise whose quarterly revenue grew 40% while RUCONEST declined.
Why Joenja’s pediatric expansion could strengthen Pharming Group’s long-term commercial runway
Find out how Pharming’s Joenja FDA review could affect PHAR stock sentiment, pediatric APDS access, and rare-disease revenue growth.